immune system
• in MOG-treated mice
|
• B cells stimulated with hyaluronan, heparan sulfate, and HMBG1 exhibit reduced cytokine over-production (IL6, IL10, IFN-gamma, TNF, and MIP-2) compared with similarly treated wild-type cells
|
• in untreated and bleomycin-treated mice
|
• in untreated and bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in untreated and bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in B cells stimulated with MOG and anti-CD40 antibodies
|
• in B cells stimulated with MOG and anti-CD40 antibodies
|
• MOG-treated mice exhibit increased histological score, more severe inflammation, increased CD8+ T cells, wider spread demyelination, decreased IgM and IgG anti-MOG antibody production, and a Th1 bias with increased IFN-gamma production compared with similarly treated wild-type mice
• adoptive transfer of B cells increased susceptibility to experimental autoimmune encephalomyelitis in recipient wild-type mice
|
• untreated and bleomycin-treated mice exhibit reduced anti-topoisomerase I, anti-U1-RNP, anti-ssDNA, anti-histone, anti-dsDNA autoantibodies compared with wild-type mice
|
• in untreated and bleomycin-treated mice
|
nervous system
• in MOG-treated mice
|
hematopoietic system
• in MOG-treated mice
|
• B cells stimulated with hyaluronan, heparan sulfate, and HMBG1 exhibit reduced cytokine over-production (IL6, IL10, IFN-gamma, TNF, and MIP-2) compared with similarly treated wild-type cells
|
• in untreated and bleomycin-treated mice
|
• in untreated and bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in untreated and bleomycin-treated mice
|
• in bleomycin-treated mice
|
homeostasis/metabolism
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• in bleomycin-treated mice
|
• bleomycin-treated mice exhibit decreased dermal infiltration (mast cells, macrophages, T and B cells), dermal thickening, skin and lung fibrosis, cytokine overproduction in the skin and serum (IL4, IL6, IL10, IFN-gamma, TNF, and MIP-2), hyaluronan overproduction, and autoantibody production compared with similarly treated wild-type mice
|
integument
• bleomycin-treated mice exhibit reduced dermal thickening compared with similarly treated wild-type mice
|
• bleomycin-treated mice exhibit reduced skin fibrosis compared with similarly treated wild-type mice
|